|
Biomarker testing rates among metastatic cancer patients with receipt of anti-cancer systemic therapy: A real-world data analysis. |
|
|
Employment - United Health Group |
Stock and Other Ownership Interests - United Health Group |
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); Exact Sciences (Inst); Exact Sciences (Inst); Genentech/Roche (Inst); Illumina (Inst); Janssen (Inst); Merck (Inst); Myriad Genetics (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst); Takeda (Inst) |
|
|
No Relationships to Disclose |
|
|
Employment - United Health Group |
Stock and Other Ownership Interests - United Health Group |
Research Funding - Cepheid (Inst); Geneticure (Inst); Illumina (Inst); Myriad Genetic Laboratories (Inst); SomaLogic (Inst) |
|
|
|
Stock and Other Ownership Interests - Illumina |
|
|
Employment - Illumina; IQvia |
Stock and Other Ownership Interests - Illumina; Pfizer (I) |
Consulting or Advisory Role - IQvia; IQvia |
|
|
|
Stock and Other Ownership Interests - Illumina |
|
|
|
Stock and Other Ownership Interests - Illumina |
|
|
Employment - Illumina; OneOncology |
Stock and Other Ownership Interests - Illumina |